NCT03066869

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Ocular Immunology and Uveitis Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.

Conditions

• Uveitis, Posterior
• Vasculitis Retinal

Interventions

Type	Name	Description
DRUG	H.P. ACTHAR GEL	H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.

Timeline

• Start date: 2017-03-22
• Primary completion: 2020-02-01
• Completion: 2020-08-01
• First posted: 2017-03-01
• Last updated: 2019-09-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study